Repligen Corporation $RGEN Shares Purchased by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC increased its holdings in Repligen Corporation (NASDAQ:RGEN – Free Report) by 1.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 954,523 shares of the biotechnology company’s stock after purchasing an additional 17,439 shares during the period. Repligen makes up about 2.0% of Stephens Investment Management Group LLC’s investment portfolio, making the stock its largest position. Stephens Investment Management Group LLC owned about 1.49% of Repligen worth $183,488,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Repligen in the 2nd quarter worth $52,000. CoreCap Advisors LLC increased its holdings in shares of Repligen by 1,275.0% in the 3rd quarter. CoreCap Advisors LLC now owns 275 shares of the biotechnology company’s stock worth $53,000 after buying an additional 255 shares during the last quarter. Bessemer Group Inc. raised its position in shares of Repligen by 38.0% during the 3rd quarter. Bessemer Group Inc. now owns 334 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 92 shares in the last quarter. Harbor Investment Advisory LLC raised its position in shares of Repligen by 198.9% during the 2nd quarter. Harbor Investment Advisory LLC now owns 523 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 348 shares in the last quarter. Finally, Trust Co. of Vermont purchased a new stake in shares of Repligen during the 2nd quarter valued at about $71,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Trading Up 6.5%

NASDAQ RGEN opened at $172.67 on Thursday. The company’s 50-day moving average price is $177.08 and its 200-day moving average price is $145.83. The company has a current ratio of 9.88, a quick ratio of 8.43 and a debt-to-equity ratio of 0.27. The stock has a market cap of $11.04 billion, a PE ratio of -822.20, a PEG ratio of 2.78 and a beta of 1.11. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $198.87.

Repligen (NASDAQ:RGEN – Get Free Report) last posted its quarterly earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.46 by $0.07. Repligen had a negative net margin of 1.47% and a positive return on equity of 5.49%. The company had revenue of $209.31 million for the quarter, compared to the consensus estimate of $206.70 million. During the same quarter last year, the firm posted $0.46 EPS. The firm’s revenue was up 10.9% compared to the same quarter last year. Equities research analysts forecast that Repligen Corporation will post 2.07 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on RGEN shares. Wells Fargo & Company lifted their price target on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. Weiss Ratings lowered Repligen from a “hold (c)” rating to a “sell (d+)” rating in a research report on Monday, November 2nd. Barclays upped their target price on Repligen from $175.00 to $225.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Zacks Research cut Repligen from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. Finally, UBS Group reiterated a “buy” rating on shares of Repligen in a report on Tuesday, September 29th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $178.57.

Get Our Latest Stock Analysis on RGEN

Repligen Profile

(Free Report)

Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.

See Also

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.